RxDoctor Payments Data

Stephanie Higby, PA

Physician Assistant · Hamilton, NYNPI 1588758403

Payments from drug & device makers

$8,380in general payments, 2019–2025

Across 409 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Amgen$825
  • Novartis$790
  • Pfizer$662
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$8,380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,380 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$170,016
Medicare patients
198
Services billed
5,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept93$699,354
Humira(Cf) PenAdalimumab51$405,272
RinvoqUpadacitinib30$184,169
EnbrelEtanercept20$171,057
Humira(Cf)Adalimumab19$148,419
Orencia ClickjectAbatacept18$96,105
Yuflyma(Cf) Autoinject (2 Pck)Adalimumab-Aaty11$84,206
BenlystaBelimumab14$68,511
SavellaMilnacipran Hcl46$31,462
Febuxostat73$17,209
MethotrexateMethotrexate Sodium451$11,883
Hydroxychloroquine Sulfate292$9,490
Leflunomide137$8,257
Duloxetine Hcl237$6,274
Celecoxib60$4,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf), Savella$1,500$364,05095 claims
AmgenEnbrel$825$171,05720 claims
GSKBenlysta$83$68,51114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Hamilton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →